Johnson & Johnson (J&J) has announced plans to separate its orthopedics unit into a new company called DePuy Synthes. This spinoff is expected to be completed within the next 18 to 24 months and marks J&J’s second major separation in two years.
Details of the Spinoff
The orthopedics division, which focuses on manufacturing hip, knee, and shoulder implants, generated approximately $9.2 billion last year. This accounted for about 10% of J&J’s total revenue. The company is currently undergoing a restructuring program for this segment, allowing it to exit certain markets and discontinue some products.
Financial Performance and Forecast
In conjunction with the spinoff announcement, J&J raised its sales forecast for 2025. The healthcare giant now projects product revenue between $93.5 billion and $93.9 billion, surpassing previous predictions and Wall Street expectations, which were at $93.4 billion.
- Third-quarter sales: $23.99 billion, exceeding expectations of $23.75 billion.
- Adjusted earnings per share: $2.80, above the anticipated $2.76.
- Pharmaceuticals sales: $15.56 billion, a 6.8% increase year-on-year.
Key products boosting pharmaceuticals sales include oncology drugs such as Darzalex, contributing $3.67 billion in third-quarter revenue. Overall, J&J’s medical device sales rose 6.8% to reach $8.43 billion, propelled by advancements in electrophysiology products.
Market Implications
Analysts from J.P. Morgan suggest that the orthopedics division accounts for about 30% of J&J’s MedTech segment but is growing slower than other parts of the business. The spinoff is expected to foster an environment for faster growth within J&J.
Chief Financial Officer Joe Wolk stated the company is considering tax-free options for the separation while remaining flexible regarding other possibilities. Despite being profitable, J&J believes that the next phase of innovation in orthopedics may be better suited elsewhere.
Looking Ahead
J&J’s stock saw a modest increase in premarket trading, having risen 32% this year, contrasting with a 3% gain in the S&P Healthcare Index. Analysts remain optimistic about J&J’s trajectory as the company navigates through current market conditions.
In summary, Johnson & Johnson’s decision to spin off its orthopedics unit reflects its strategic focus on high-growth and high-margin areas while responding to market demands and ensuring robust financial performance.
